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Background: Oats contain hydroxycinnamoyl anthranilates, also named avenanthramides (Avn), which have
beneficial health properties because of their antioxidant, anti-inflammatory, and antiproliferative effects. The
microbial production of hydroxycinnamoyl anthranilates is an eco-friendly alternative to chemical synthesis or
purification from plant sources. We recently demonstrated in yeast (Saccharomyces cerevisiae) that coexpression
of 4-coumarate: CoA ligase (4CL) from Arabidopsis thaliana and hydroxycinnamoyl/benzoyl-CoA/anthranilate
N-hydroxycinnamoyl/benzoyltransferase (HCBT) from Dianthus caryophyllusenabled the biological production of
several cinnamoyl anthranilates upon feeding with anthranilate and various cinnamates. Using engineering
strategies to overproduce anthranilate and hydroxycinnamates, we describe here an entire pathway for the
microbial synthesis of two Avns from glucose in Escherichia coli.
Results: We first showed that coexpression of HCBT and Nt4CL1 from tobacco in the E. coli anthranilate-accumulating
strain W3110 trpD9923 allowed the production of Avn D [N-(4′-hydroxycinnamoyl)-anthranilic acid] and Avn F [N-(3′,4′-
dihydroxycinnamoyl)-anthranilic acid] upon feeding with p-coumarate and caffeate, respectively. Moreover, additional
expression in this strain of a tyrosine ammonia-lyase from Rhodotorula glutinis (RgTAL) led to the conversion of
endogenous tyrosine into p-coumarate and resulted in the production of Avn D from glucose. Second, a 135-fold
improvement in Avn D titer was achieved by boosting tyrosine production using two plasmids that express the eleven
genes necessary for tyrosine synthesis from erythrose 4-phosphate and phosphoenolpyruvate. Finally, expression of
either the p-coumarate 3-hydroxylase Sam5 from Saccharothrix espanensis or the hydroxylase complex HpaBC from E.
coli resulted in the endogenous production of caffeate and biosynthesis of Avn F.
Conclusion: We established a biosynthetic pathway for the microbial production of valuable hydroxycinnamoyl
anthranilates from an inexpensive carbon source. The proposed pathway will serve as a platform for further engineering
toward economical and sustainable bioproduction of these pharmaceuticals and other related aromatic compounds.
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Biological synthesis, Escherichia coliBackground
Hydroxycinnamoyl anthranilates are part of the large
cinnamoyl anthranilates family, a class of molecules with
beneficial health properties. For example, avenanthramides
(Avns) are natural hydroxycinnamoyl anthranilates found
in oats (Avena sativa L.) at low concentrations (a few parts* Correspondence: dloque@lbl.gov
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reproduction in any medium, provided the orper million in grains) and whose antioxidant, anti-
inflammatory, and antiproliferative effects are considered to
contribute to the health benefits of oatmeal consumption
[1-6]. The antioxidant effects of Avns have been established
in several animal studies [7-9], and their anti-inflammatory
properties illustrated in model systems of atherosclerosis,
diabetes, itching, and breast cancer. In particular, Avn-
enriched oat extracts, synthetic dihydroavenanthramide
D (DHAvn D) and Avn C methyl ester (CH3-Avn C)
(Figure 1A) were shown to inhibit the activation of the NF-
κB transcription factor, which is a master regulator of infec-
tion and inflammation [10-14]. Consequently, DHAvn Dtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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skin disorders [15]. Lastly, the antiproliferative effects of
Avn have been demonstrated on vascular muscle and co-
lonic cancer cell lines [16-18]. Similarly, tranilast [N-(3′4′-
dimethoxycinnamoyl)-anthranilic acid] (Figure 1A) is a syn-
thetic cinnamoyl anthranilate used as an antihistamine in
Japan and South Korea for the treatment of allergic disor-
ders, hypertrophic scars, and keloids [19-21]. Tranilast has
anti-inflammatory and antiproliferative effects and is cur-
rently evaluated clinically for the treatment of multiple
sclerosis and various arthritic conditions [22-24]. Moreover,
the antitumor potential of tranilast has been evidenced in
several clinical trials [25], and the design of analogues that
exhibit higher anti-fibrotic activity has been extensively in-
vestigated [26-30].
Using microbes for biological synthesis of therapeutic
drugs or precursors offers an alternative production
strategy to commonly employed methods such as direct
extraction from source organisms or chemical synthesis.
Microbial expression systems have several advantages
such as reduced requirements for toxic chemicals and
natural resources; consistent quality; scalability; simple
extraction; and potential for higher synthesis efficiency
[31,32]. Taking into consideration the expanding number
of therapeutic applications for cinnamoyl anthranilates,
as well as the fact that these molecules are currently syn-
thesized chemically or extracted from food sources
[33,34], we attempted to design a pathway for their den
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Figure 1 General structure of cinnamoyl anthranilates. (A) Tranilast, DHAvn D, and CH3-Avn C are represented. The two cinnamoyl
anthranilates (Avn D and Avn F) produced biologically in this study are shown n=1, single carbon bond; n=2, double carbon bond. (B) Enzymatic
reaction catalyzed by HCBT for the synthesis of Avn D.novo production from glucose using E. coli as a produc-
tion platform.
HCBT is an acetyltransferase from the BAHD family
[35], which couples p-coumaroyl-CoA with anthranilate
via an amide bond to produce Avn D (Figure 1B) [36];
while 4CL enzymes convert cinnamates into their corre-
sponding CoA thioesters [37]. We previously engineered
a yeast strain that coexpresses 4CL and HCBT for the
production of several cinnamoyl anthranilates, such as
Avn D and Avn F, upon feedings with anthranilate and
various cinnamates. This highlighted the potential of
using these enzymes for the biological production of
cinnamoyl anthranilates [38]. E. coli is a host of choice
for the expression of complex pathways and the produc-
tion of elaborate molecules such as aromatic compounds
from cheap carbon sources [39,40].
In this study, we primarily focused on the biological syn-
thesis of Avn D, which features a basal core structure of
hydroxycinnamoyl anthranilates. For this purpose, a previ-
ously characterized E. coli anthranilate-accumulating
strain was selected as a chassis [41,42]. In that strain,
coexpression of Nt4CL1 and HCBT led to the produc-
tion of Avn D and Avn F when the culture medium
was supplemented only with p-coumarate and caffeate,
respectively. This validated the functional expression
and activity of both plant enzymes in our chassis. The
production system was then affranchised from precur-
sor feeding by additional expression of RgTAL, which
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Avn D biosynthesis was further enhanced by expressing
a two-plasmid-based modular biosynthetic pathway for
tyrosine overproduction from glucose [45]. Finally, Avn F
was also biologically produced de novo upon expression
of either Sam5 or HpaBC, which are two hydroxylases that
convert p-coumarate into caffeate [46,47].
Results and discussion
Expression of Nt4CL1 and HCBT in E. coli strain W3110
trpD9923
E. coli W3110 trpD9923 strain is a tryptophan auxotroph
that over-accumulates anthranilate due to a nonsense
mutation in the trpD gene, which abolishes anthranilate
phosphoribosyltransferase activity but does not affect
anthranilate synthase activity [41,42]. This strain was
shown to be suitable for metabolic engineering because ex-
pression of genes from the shikimate pathway further in-
creased anthranilate production [41]. We first constructed
pAvn plasmid for coexpression of Nt4CL1, which encodes
a 4CL that converts p-coumarate and caffeate into their
corresponding CoA thioesters [48], and HCBT. To confirm
that HCBT can catalyze the condensation of coumaroyl-
CoA with anthranilate and produce Avn D in W3110
trpD9923, the strain was transformed with pAvn and
grown in the presence of p-coumarate as a precursor. Cul-
tures of W3110 trpD9923 harboring an empty vector were
also grown as a negative control. Only in the case of the
strain expressing pAvn, LC-TOF MS analysis of the culture
medium revealed a peak (Rt = 11.75 min) that corresponds
to Avn D by comparison with an authentic standard solu-
tion (Figure 2A). Similarly, the engineered strain produced
some Avn F (Rt = 10.56 min) when p-coumarate wasA BRt= 11.75 min
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Figure 2 Production of Avn D and Avn F in engineered E. coli coexpr
the culture medium of the W3110 trpD9923 strain harboring the pAvn vect
MS spectra were obtained after LC-TOF MS analysis of the culture medium
solutions (lower panels).substituted by caffeate in the medium (Figure 2B). This re-
sult confirms the affinity of HCBT for caffeoyl-CoA. It also
demonstrates secretion of Avn outside of the production
host, because the Avn D and Avn F content inside E. coli
cells represented less than 5% of the amount quantified
from the medium (data not shown).
Biosynthesis of Avn D from glucose and titer
improvement using a tyrosine overproduction strategy
To produce Avn D — without supplying costly precursors
such as p-coumarate to the engineered E. coli strain — we
designed a plasmid (pAvnD) that contains in a single op-
eron HCBT, Nt4CL1, and a gene encoding RgTAL for the
conversion of tyrosine into p-coumarate (Figure 3A, B).
Analysis of the culture medium of cells harboring pAvnD
and grown for 24 hours revealed the presence of p-
coumarate (1.0 ± 0.1 μM), which was produced from en-
dogenous tyrosine upon RgTAL activity, and a detectable
amount of Avn D (~200 nM) (Table 1). Moreover, a 15%
reduction of the final biomass density was observed for
this strain compared to the control. We recently reported
on a strategy for the overproduction in E. coli of tyrosine
using two plasmids (pS0 and pY) that contain all the genes
required for the synthesis of tyrosine from erythrose 4-
phosphate and phosphoenolpyruvate (Figure 3A, B) [45].
As expected, this strategy applied to the W3110 trpD9923
strain not only increased tyrosine titers (665-fold), but also
enhanced anthranilate production (3.5-fold), since both
metabolites are derived from chorismate via the shikimate
pathway (Figure 3A; Table 1). This engineered strain, des-
pite having a slower growth rate, showed no difference in
final biomass density compared to that harboring empty vec-
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Figure 3 Biosynthetic pathways for the microbial production of hydroxycinnamoyl anthranilates from glucose. (A) Three compatible
plasmids were used for the biological production of Avn D and Avn F from glucose. A first plasmid is a shikimate module which contains all the
six genes for the production of shikimate (SHIK) from pyruvate (PYR), fructose 6-phosphate (F6P), and glyceraldehydes 3-phosphate (G3P) (orange
box). A second plasmid is a tyrosine module which contains all the five genes for the production of tyrosine (TYR) from SHIK (green box). The
third plasmid is the cinnamoyl anthranilate module which contains up to five genes for the conversion of TYR into two hydroxycinnamoyl-CoAs
and their coupling to anthranilate (ANT) for the production of Avn D and Avn F (blue box).CAFA, caffeate; CAF-CoA, caffeoyl-CoA; CHA, chorismate;
COUA, p-coumarate; COU-CoA, p-coumaroyl-CoA; DAHP, 3-deoxy-D-arabino-heptulosonate; DHQ, dehydroquinate; DHS, dehydroshikimate; E4P,
erythrose 4-phosphate; EPSP, 5-enolpyruvoylshikimate 3-phosphate; HPP, 4 hydroxyphenlypyruvate; PEP, phosphoenolpyruvate; PPA, prephenate; and
S3P, shikimate 3-phosphate. The enzymes (in bold face) are as follows: PpsA, phosphoenolpyruvate synthase; TktA, transketolase A; AroG, DAHP
synthase; AroB, DHQ synthase; AroD, DHQ dehydratase; YdiB, shikimate dehydrogenase; AroL, shikimate kinase II; AroA, EPSP synthase; AroC, chorismate
synthase; TrpE/D, anthranilate synthase I/II; TyrA, chorismatemutase/prephenate dehydrogenase; and TyrB, tyrosine aminotransferase; TAL, tyrosine
ammonia-lyase; 4CL, p-coumarate:CoA ligase; COUA3H, p-coumarate 3-hydroxylase; HCBT, hydroxycinnamoyl/benzoyl-CoA/anthranilate N-
hydroxycinnamoyl/benzoyltransferase. The dashed lines indicate where feedback inhibitions occur. Allosteric regulation of AroG and TyrA were
removed by employing their respective feedback-resistant mutants, AroG* (D146N) and TyrA* (M53I; A354V), respectively. (B) Structures of the three
plasmids used for cinnamoyl anthranilates production. The open blocks indicate the origins of replication, the open arrows represent the genes, and
the angled arrows indicate the promoters.
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to a 135-fold increase in extracellular Avn D (27.3 ± 0.1 μM)
compared to the production achieved using pAvnD alone,
after 24 h of culture (Table 1). The analysis of the culture
medium also revealed that p-coumarate content (~32 μM)
was much lower compared to that of tyrosine (~6 mM),
suggesting that RgTAL is a rate-limiting enzyme in the path-
way (Table 1). As observed for the strain containing pAvnD
alone, the strain harboring the three plasmids had a
15% reduction of the final biomass density.
Conversion of p-coumarate into caffeate and production
of Avn F using Sam5
For the biological production of caffeate, and ultimately
Avn F, we generated pAvnDF1 plasmid, which adds into
the pAvnD backbone sam5 under the control of the trc
promoter (Figure 3A, B). Sam5 is a p-coumarate 3-
hydroxylase that has been successfully expressed in E.Table 1 Production of Avn D and precursors by engineered W
Plasmids Compounds (μM)
Anthranilate T
Empty pZS21 + pBbB5a 1646 ± 63 9
pS0 + pY 5878 ± 311 6
pAvnD 1564 ± 58 6
pS0 + pY + pAvnD 5780 ± 251 5
Values are the means ± SD of five independent clones. nd not detected.coli for the biological synthesis of caffeate [49-51].
Expression of the genes harbored on pAvnDF1 plasmid
in the W3110 trpD9923 strain resulted in the production
of a small amount of caffeate in the culture medium, but
no Avn could be detected (Table 2). However, co-
transformation of pAvnDF1 with pS0 and pY not only
enhanced caffeate production (~230-fold), but also led
to the biosynthesis of Avn F (~110 nM) in addition to
Avn D (Table 2). No extracellular p-coumarate could be
detected in these cultures, suggesting that most of it was
efficiently converted into caffeate by Sam5.
Interestingly, LC-TOF MS analysis revealed an add-
itional new peak in the culture medium of the strains
harboring pAvnDF1 and expressing Sam5. This peak
was found to correspond to 3,4,5-trihydroxycinnamate
based on the mass and elution time of an authentic
standard (Additional file 1: Figure S1), and the 3,4,5-
trihydroxycinnamate content represented ~ 1.6 μM in3110 trpD9923 E. coli strains
yrosine p-Coumarate Avn D
.3 ± 1.3 nd nd
201 ± 598 nd nd
.8 ± 0.9 1.0 ± 0.1 0.2 ± 0.1
963 ± 219 32.6 ± 3.4 27.3 ± 1.4
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and reached 48 μM when the tyrosine production path-
way (pS0 + pY) was co-expressed in the pAvnDF1-
containing strain. These observations strongly suggest
that Sam5 can not only convert p-coumarate into
caffeate, but also caffeate into 3,4,5-trihydroxycinnamate.
To validate this hypothesis, an E. coli strain expressing
Sam5 alone was grown in the presence of caffeate and
the culture medium analyzed for the presence of 3,4,5-
trihydroxycinnamate. Conclusively, this new compound
was detected in the medium of the Sam5 strain but not
in that of an empty vector control strain (Figure 4).This
is, to our knowledge, the first report of an enzyme cap-
able of hydroxylating caffeate. Although the conversion
of caffeate into 3,4,5-trihydroxycinnamate is not desir-
able for the production of Avn F (and perhaps inhibitory
for Nt4CL1 activity), this novel hydroxylating property
for Sam5 presents an opportunity for the enzymatic syn-
thesis of trihydroxylated cinnamoyl anthranilates. In this
regard, we previously demonstrated in yeast the wide-
range of substrate specificity for Arabidopsis 4CL5 and
HCBT toward various substituted cinnamates and
cinnamoyl-CoAs, respectively [38].Conversion of p-coumarate into caffeate and production
of Avn F using the HpaBC complex
The enzyme complex consisting of a 4-hydroxyphenylacetate
3-hydroxylase (HpaB) and a flavin:NADH reductase
(HpaC) from E. coli was tested for the biological pro-
duction of caffeate and Avn F. The operon hpaBC is
involved in 4-hydroxyphenylacetate degradation and
several studies showed that the HpaBC enzyme com-
plex can accept a broad range of substrates including
tyrosine and p-coumarate [46,52,53]. We constructed a
pAvnDF2 plasmid by placing the hpaBC operon under
the control of the trc promoter into pAvnD plasmid
(Figure 3B). Transformation of pAvnDF2 into E. coli
W3110 trpD9923 resulted in the production of small
amount of caffeate in the culture medium, but only Avn D
could be detected (Table 2). By contrast, co-transformation
of pAvnDF2 with pS0 and pY enhanced caffeate production
(~115-fold) and led to the biosynthesis of Avn F (~540 nM)
in addition to Avn D (Table 2). Unlike the results of theTable 2 Production of Avn F and precursors by engineered W
Plasmids Compounds (μM)
Anthranilate Tyrosine p-
pAvnDF1 1498 ± 76 6.0 ± 1.0 nd
pS0 + pY + pAvnDF1 5802 ± 298 6286 ± 150 nd
pAvnDF2 1521 ± 44 2.0 ± 0.2 0.1
pS0 + pY + pAvnDF2 5644 ± 288 2503 ± 313 11
Values are the means ± SD of five independent clones. nd not detected.biosynthesis of Avn F using Sam5, the expression of HpaBC
maintained higher Avn D titers and did not produce any
3,4,5-trihydroxycinnamate nor entirely deplete p-coumarate
content. This suggests that HpaBC is less efficient than
Sam5 at converting p-coumarate into caffeate in our sys-
tem, yet nevertheless Avn F titers using HpaBC were ~5-
fold higher compared to those achieved using Sam5
(Table 2). Alternatively, the higher caffeate content and
lower AvnF titers obtained using Sam5 could reflect a nega-
tive effect of 3,4,5-trihydroxycinnamate on 4CL1 activity.
Moreover, we observed a reduction in tyrosine titers com-
pared to those measured from the culturesof E. coli W3110
trpD9923 harboring pAvnD or pAvnDF1. This was prob-
ably due to HpaBC activity, which can also convert tyrosine
into L-dopa. Conclusively, we found that L-dopa concentra-
tion was ~4.4 mM in the culture medium of the pS0/pY/
pAvnDF2 strain. Furthermore, based on previous studies
showing that some tyrosine ammonia-lyases convert L-
dopa into caffeate [46,54], an E. coli strain that expresses
RgTAL alone was created and grown in the presence of L-
dopa. Interestingly, analysis of the culture medium of the
RgTAL strain revealed the presence of caffeate, which was
absent in the medium of an empty vector control strain
(Figure 5). These results demonstrate that RgTAL exhibits
some L-dopa ammonia-lyase activity and suggest that part
of the caffeate produced in the strains harboring pAvnDF2
could be derived from L-dopa.Conclusions
This work is an example of biological production of valu-
able aromatic metabolites using a tyrosine-overproducing
strategy applied to an anthranilate-accumulating strain.
Considering the anthranilate titers achieved with the
strain containing only the shikimate and tyrosine modules,
the maximum theoretical yield for Avn D in this back-
ground would be ~5.8 mM. However, much lower Avn D
titers were obtained for the strain harboring pS0, pY and
pAvnD, probably due to poor conversion of tyrosine into
p-coumarate as previously observed in various studies
using heterologous expression of TALs [46,49,50], and po-
tentially to the limited intracellular pools of coenzyme A
availability [55]. It is particularly noteworthy that, because
of its specificity to anthranilate as an acceptor, the BAHD3110 trpD9923 E. coli strains
Coumarate Caffeate Avn D Avn F
0.28 ± 0.07 nd nd
65.1 ± 8.3 0.07 ± 0.00 0.11 ± 0.04
0 ± 0.01 0.13 ± 0.03 0.03 ± 0.00 nd
























Figure 4 In-vivo enzyme activity of Sam5 towards caffeate.
Production of 3,4,5-trihydroxycinnamate detected in the culture
medium of an E. coli strain expressing Sam5 and fed with caffeate.
Error bars indicate mean values ± SD from three independent clones.
Nd, not detected.
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thesis of cinnamoyl anthranilates. For instance, no mass
peaks corresponding to other phenylpropenoyl-amino
acid amides consisting of a tryptophan, tyrosine or an L-
dopa moiety — nor to hydroxycinnamate esters of
shikimate or quinate — could be detected in the culture



















Figure 5 In-vivo enzyme activity of RgTAL towards L-dopa.
Production of caffeate detected in the culture medium of an E. coli
strain expressing RgTAL and fed with L-dopa. Error bars indicate
mean values ± SD from three independent clones. Nd, not detected.The discovery that RgTAL has L-dopa ammonia-lyase
(DAL) activity is of interest and provides some opportun-
ities for the design of new enzymes with a higher DAL/
TAL activity ratio. In combination with tyrosine hydroxy-
lase complexes such as HpaBC, such engineered DALs
could be used to improve the bioproduction of caffeate
from tyrosine via L-dopa and without generating p-
coumarate as an intermediate, a competitive precursor for
the biosynthesis of Avn F. Furthermore, the impact of ex-
pressing in our system 4CLs other than Nt4CL1 should be
considered; especially in regard to production of Avn F,
because Nt4CL1 is known to be less active with caffeate as
a substrate compared to p-coumarate [56,57]. Finally, our
rationally designed pathway can serve as a framework for
improvement of Avn production using combinatorial ap-
proaches that have been shown previously to increase tyro-
sine production [58]. As an adjunct to the recent
development of procedures that use safe methylating agents
[59], this study describes a basis for eco-friendly production
of cinnamoyl anthranilates such as Avn D and Avn F and
can serve as a scaffold for the synthesis of more elaborate
molecules such as tranilast and its analogs.
Methods
Chemicals and enzymes
The following chemicals and enzymes were used in
this study: p-coumarate, L-tyrosine, anthranilate, L-dopa,
isopropyl-β-D-thiogalactopyranoside (IPTG) (Sigma-Aldrich,
St. Louis, MO, USA), caffeate (MPBiomedicals, Solon,
OH, USA), 3,4,5-trihydroxycinnamate (Apin Chemicals
Ltd, Abingdon, UK), restriction enzymes (NEB,
Ipswich, MA, USA), PhusionHigh-Fidelity DNA Poly-
merase (Thermo Scientific, Waltham, MA, USA),
Rapid DNA ligase Kit (Roche Applied Science, Indianapolis,
IN, USA). All the enzymes were used in accordance
with instructions provided by the manufacturers. N-(4′-hy-
droxy-(E)-cinnamoyl)-anthranilate (Avn D) and N-(3′,4′-
dihydroxy-(E)-cinnamoyl)-anthranilate (Avn F) were pre-
pared as described [1,38].
Strains, plasmids, media, and growth conditions
E. coli DH10B (Life technologies, Foster City, CA, USA)
was used for gene cloning and plasmid propagation.
Bacterial strains and plasmids used in this study are de-
scribed in Table 3. E. coli strain W3110 trpD9923 was
obtained from the E. coli Genetic Stock Center (Yale Uni-
versity, New Haven, CT). E. coli cells for gene cloning and
plasmid propagation were grown in Luria-Bertani (LB)
medium at 37°C. For cinnamoyl anthranilate production,
E. coli W3110 trpD9923 was used and cultured at 37°C
in MOPS (morpholinepropanesulfonic acid)-M9 minimal
medium [60] containing 1% glucose, 10 μg/mL vitamin B1,
20 μg/mL tryptophan, and supplemented with the appro-
priate amounts of antibiotics: carbenicillin (100 μg/ml),
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Independent clones were first streaked onto solid MOPS-
M9 minimal medium. 10-ml cultures in flasks were started
at OD600 = 0.05 from overnight cultures, and induced eight
hours later by addition of IPTG to a final concentration of
0.1 mM. For feeding experiments, 300 μM p-coumarate or
caffeate was added to the medium at the time of induction.
Samples used to analyze tyrosine, anthranilate, p-
coumarate, caffeate, L-dopa, 3,4,5-trihydroxycinnamateand
cinnamoyl anthranilates content were collected after 24
hours of culture. E. coli BL21(DE3) was used and cultured
at 37°C in MOPS-M9 minimal medium containing 1%
glucose and carbenicillin (100 μg/ml) or kanamycin
(50 μg/ml) for in-vivo enzyme activities. 10-ml cultures in
flasks were started at OD600 = 0.05 from overnight cultures
of clones containing pSam5 or pRgTAL, and induced and
fed 5 hours later by addition of IPTG (0.1 mM) and
caffeate (200 μM) or L-dopa (100 μM), respectively. Sam-
ples used to analyze 3,4,5-trihydroxycinnamate and caffeate
were collected after 24 hours of culture.
Construction of plasmids
The BglBricks cloning strategy and the BglBricks vectors
[62,63] were used for gene assembly. All the forwardTable 3 Plasmids and strains used in this study
Plasmid or Strain Description
Base plasmids
pZS21 pSC101; Kanr PLtetO-1
pBbB5a pBBR1; AmprlacI PlacUV5
pBbA5c p15A; CmrlacI PlacUV5
pBbE1a colE1; AmprlacIPtrc














W3110 trpD9923 W3110 [F-λ- INV (rrnD-r
mutagenized by treatm
DH10B Cloning host
BL21(DE3) Expression hostprimers consist of a BglII restriction site at the 5′-end,
followed by the Shine-Dalgarno sequence prior to the
start codon. The reverse primers consist of the XhoI and
BamHI restriction sites at the 5′-end. For the pAvn con-
struct, the gene sequence encoding HCBT (GenBank:
CAB06427) from [38] was amplified using the primers
HCBTfw and HCBTrv listed in Additional file 2: Table
S1. The PCR product was digested with BglII / XhoI and
ligated into the pBbA5c plasmid [56] between theBamHI
and XhoI restriction sites. The cDNA clone correspond-
ing to Nt4CL1 (GenBank: U50845) from [48] was ampli-
fied using the primers 4CLfw and 4CLrv (Additional file
2: Table S1), digested with BglII / XhoI and ligated into
the pBbA5c::HCBT construct previously digested with
BamHI / XhoI to yield the pAvn plasmid.
For the construction of pAvnD, a gene sequence encoding
RgTAL (GenBank: AAA33883) was synthesized (Genescript,
NJ, USA) and amplified using the primers TALfw and
TALrv listed in Additional file 2: Table S1. The PCR product
was digested with BglII / XhoI and ligated downstream
Nt4CL1 into pAvn previously digested with BamHI / XhoI.
The RgTAL gene sequence was also ligated downstream the
T7 promoter into the pBbE7k plasmid [62] between the
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Sam5 (GenBank: ABC88666.1) was synthesized (Genescript,
NJ, USA) with the BglBricks restriction sites EcoRI and BglII
followed by the Shine-Dalgarno sequence at the 5′-end, and
with BamHI and XhoI restriction sites at the 3′-end. The
sam5 fragment was released by BglII / XhoI digestions and
cloned between the BamHI and XhoI sites of the pBbE1a
plasmid [63], downstream the terminator – promoter com-
bination sequence T1-Ptrc, to yield the pSam5 plasmid. The
T1-Ptrc-Sam5 fragment was released from pSam5 with BglII /
XhoI digestions and ligated downstream RgTAL into pAvnD
previously digested with BamHI and XhoI.
For the pAvnDF2 construct, the hpaBC operon,
which encodes HpaB (GenBank: CAQ34705) and
HpaC (GenBank: CAQ34704) was amplified from
E. coli BL21 (DE3) genomic DNA using primers
hpaBCfw and hpaBCrv (Additional file 2: Table S1).
The PCR product was ligated into the pCR-4Blunt-
TOPO vector (Life technologies, Foster City, CA,
USA) and a sequenced-verified clone was cured by
site-directed mutagenesis to remove an internal BglII
restriction site (nucleotides 83–88) using the primers
SDM-BglIIfw and SDM-BglIIrv (Additional file 2:
Table S1). The cured hpaBC operon was cloned into
the pBbE1a plasmid downstream the T1-Ptrc sequence.
The T1-Ptrc-hpaBC fragment was released with BglII /
XhoI digestions and ligated downstream RgTAL into
pAvnD previously digested with BamHI and XhoI. For the
construction of the pY plasmid, the tyrosine operon in the
pY1 plasmid [45] was released with BglII / XhoI digestions
and cloned into the pBbB5a plasmid between the BamHI
and XhoI restriction sites.
LC-MS analysis of cinnamoyl anthranilates and precursors
All metabolites were quantified using HPLC–electrospray
ionization (ESI)–time-of-flight (TOF) MS. An aliquot of
the culture medium was cleared by centrifugation
(21,000xg, 5 min, 4°C), mixed with an equal volume of
cold methanol–water (1:1, v/v), and filtered using Amicon
Ultra centrifugal filters (3,000 Da MW cut off regenerated
cellulose membrane; Millipore, Billerica, MA) prior to
analysis. For the quantification of intracellular Avn, a cell
pellet from 5 ml of culture was washed three times with
water, suspended in cold methanol–water (1:1, v/v), soni-
cated twice for 30 s and centrifuged (21,000xg, 5 min,
4°C). The supernatant was collected and filtered before
analysis. The separation of metabolites was conducted
on the fermentation-monitoring HPX-87H column
with 8% cross-linkage (150-mm length, 7.8-mm inside
diameter, and 9-μm particle size; Bio-Rad, Richmond,
CA) using an Agilent Technologies 1100 Series HPLC
system. A sample injection volume of 10 μl was used
throughout. The sample tray and column compart-
ment were set to 4 and 50°C, respectively. Metaboliteswere eluted isocratically with a mobile-phase compos-
ition of 0.1% formic acid in water at a flow rate of
0.5 ml/min. The HPLC system was coupled to an
Agilent Technologies 6210 series time-of-flight mass
spectrometer (for LC-TOF MS) via a MassHunter
workstation (Agilent Technologies, CA). Drying and
nebulizing gases were set to 13 liters/min and 30 lb/
in2, respectively, and a drying-gas temperature of 330°C
was used throughout. ESI was conducted in the nega-
tive ion mode and a capillary voltage of −3,500 V was
utilized. All other MS conditions were described previ-
ously [38]. Metabolites were quantified via seven-point
calibration curves of authentic standard compounds
for which the R2 coefficients were ≥0.99.Additional files
Additional file 1: Figure S1. LC-TOF MS analysis of 3,4,5-
trihydroxycinnamate produced by engineered E. coli. (A) A sample from
the medium of the strain harboring pAvnDF1 after 24 hours of culture.
(B) Standard, 25 μM 3,4,5-trihydroxycinnamate solution.
Additional file 2: Table S1. Primers used in this study.
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